Fractyl Health is a metabolic therapeutics company focused on the treatment of metabolic diseases. Co.'s lead product candidate, the Revita DMR System, is an outpatient procedural therapy designed to durably modify duodenal dysfunction and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. Co. is also developing Rejuva, a locally administered, adeno-associated virus delivered pancreatic gene therapy platform designed to enable long-term remission of type 2 diabetes and obesity by durably altering metabolic hormone function in the pancreatic islet cells. The GUTS average annual return since 2024 is shown above.
The Average Annual Return on the GUTS average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GUTS average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GUTS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|